Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | IL6 | P05231 | 1/20 | 0.35 |
| ▸ | C1R | P00736 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315421 | 0.83 | ALDH1A1 (0.40) | PARP1CES1NOTUMPSMB8MAP3K5 | |
| SCHEMBL18331030 | 0.76 | PARP1 (0.54) | PARP1PSMB5PDE3BPDE3A | |
| SCHEMBL30779660 | 0.76 | PARP1 (0.54) | PARP1PSMB5PDE3BPDE3A | |
| SCHEMBL1508794 | 0.75 | PARP1 (0.46) | PARP1PSMB5PDE3BPDE3A | |
| SCHEMBL22859743 | 0.74 | METAP1 (0.43) | CES1NOTUMPSMB8GALR1METAP1 | |
| SCHEMBL5534959 | 0.73 | PARP1 (0.56) | PARP1PSMB5MEN1KMT2A | |
| SCHEMBL30525259 | 0.73 | MAOA (0.42) | CES1ARNOTUMPSMB8GALR1 | |
| SCHEMBL2319912 | 0.72 | KMT2A (0.41) | CES1NOTUMMETAP1MEN1KMT2A | |
| SCHEMBL5534964 | 0.72 | PSMB5 (0.61) | PARP1PSMB5ARMEN1KMT2A | |
| SCHEMBL3976344 | 0.72 | PARP1 (0.54) | PARP1PSMB5CES1NOTUMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3045456-B1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-20170020875-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-20170020876-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9481672-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-01 | — | — | US | disclosed |
| EP-3045456-A1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2289868-B1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | PARP1 3945/4885PSMB5 3679/4885CES1 72/4885 |
| US-20170020875-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
| US-20170020876-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PARP1 144/4885PSMB5 3482/4885CES1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.